Ferrous Bisglycinate for Health & Longevity

Evidence Review created on 11/08/2026 using AI4L + evidence-mcp / Opus 5.5

Also known as: Iron Bisglycinate, Ferrous Bisglycinate Chelate, Iron Bisglycinate Chelate, Ferrous Glycinate, Iron Glycinate, Iron(II) Glycinate, Ferrous Bis-Glycine Chelate, Iron Amino Acid Chelate, Ferrochel, Aminojern

Motivation

Ferrous bisglycinate is a form of supplemental iron in which each iron atom is bound to two molecules of glycine, a simple amino acid. It is sold as a gentler, better-absorbed alternative to classic iron salts such as ferrous sulfate, and it is one of the most common iron forms in supplements bought by health-conscious adults, especially menstruating women, endurance athletes and regular blood donors.

Iron is a double-edged nutrient for anyone focused on long-term health. Too little iron causes anemia and tiredness, while the body has no active way to excrete surplus iron, and genetic studies have asked how lifelong iron levels relate to lifespan. Interest in this particular form grew because nausea, abdominal discomfort and constipation are common reasons people stop taking iron salts.

This review examines the human evidence on what ferrous bisglycinate does for iron status and energy, its side effects and long-term risks, how it compares with other iron forms, and how it is dosed, combined with medications and monitored.

Benefits - Risks - Protocol - Conclusion

This section lists expert commentary and a narrative review that give a high-level overview of iron supplementation, ferrous bisglycinate and the risks of excess iron.

Four items are listed because no further content met the depth requirement. Peter Attia’s full iron episode (AMA #58) is members-only, so only its free preview is listed, and Rhonda Patrick’s iron episode (Aliquot #137) is members-only, so its content cannot be reviewed; Andrew Huberman’s only iron discussion is a three-minute segment of a broader aging episode, and Lifespan.io’s site search returned no article on iron supplementation.

Grokipedia

  • Iron bisglycinate

    Summarizes chemistry, absorption and tolerability claims, and notes that higher-dose ferrous sulfate outperformed lower-dose bisglycinate on ferritin in some trials; it is AI-written, so the primary studies remain the reference.

Examine

  • Iron

    Examine has no page dedicated to ferrous bisglycinate; its Iron page grades the evidence for iron supplementation overall and lists iron-amino acid chelates, including ferrous bisglycinate, among available forms.

ConsumerLab

Systematic Reviews

This section lists the systematic reviews and meta-analyses that analyze ferrous bisglycinate itself.

The principal risk, gastrointestinal adverse events, is covered by Fischer 2023; no systematic review addresses the long-term risk of iron accumulation with ferrous bisglycinate.

Mechanism of Action

Ferrous bisglycinate is ferrous (Fe²⁺) iron bound to two glycine molecules, a small chelate (a ring-shaped metal–ligand complex) that stays soluble in the gut. A narrative review finds its iron absorption affected by dietary enhancers and inhibitors, but less than from ferrous sulfate (Hertrampf 2004). Phytate (a mineral-binding compound in grains and legumes) illustrates this: from whole-maize porridge, iron from ferrous bisglycinate was absorbed four times better than iron from ferrous sulfate (Bovell-Benjamin 2000).

Two explanations compete for how it crosses the gut wall. One holds that the chelate is taken up intact by a separate route; the other is supported by competition studies showing that its iron joins the ordinary nonheme-iron (non-meat iron) pool used by iron salts (Pizarro 2002). That pool enters gut cells through DMT1 (divalent metal transporter 1, the main iron importer of the intestine).

Absorption from ferrous bisglycinate is regulated by iron status (Bovell-Benjamin 2000). The control signal is hepcidin (a liver hormone that blocks ferroportin, the channel exporting iron from gut cells into blood). In iron-depleted women, oral iron doses of 60 mg or more raised hepcidin and cut absorption the next day by 35–45% (Moretti 2015).

Pharmacology: iron has no conventional half-life, since absorbed iron is recycled, not excreted. Transferrin (the blood iron carrier) delivers it mainly to bone marrow; surplus is stored as ferritin in liver, spleen and muscle. There is no receptor selectivity and no cytochrome P450 (liver drug-metabolizing enzyme) metabolism; the glycine joins the amino acid pool.

Historical Context & Evolution

Ferrous bisglycinate was developed by Albion Laboratories in Utah and marketed as Ferrochel. Its original intended use was food fortification and treatment of iron-deficiency anemia. In 1999 the US Food and Drug Administration (FDA) raised no questions about Albion’s notice that it is generally recognized as safe for iron enrichment and fortification of foods (FDA GRN 19). Albion’s own toxicology work reported a no-observed-adverse-effect level of 500 mg/kg body weight per day in rats, the highest dose tested (Jeppsen 1999); its lead author worked for the manufacturer.

A narrative review of studies from the 1990s and early 2000s found it better absorbed than ferrous sulfate from milk, wheat and maize products, with absorption still regulated by iron stores (Hertrampf 2004). The same review names cost as the main limitation to its use in national fortification programs (Hertrampf 2004).

Health-optimizing adults came to it for tolerability: iron salts commonly cause nausea and abdominal discomfort, and the chelate was promoted as gentler at lower doses. In parallel, the longevity community inherited an older worry. In 1981 Sullivan proposed that higher stored iron explains why men and postmenopausal women have more heart disease than premenopausal women (Sullivan 1981). What changed was the arrival of genetic methods able to test causation: such studies link higher iron to less hypercholesterolemia (high blood cholesterol) (Gill 2019), more skin infections (Gill 2019), and a shorter parental lifespan (Daghlas 2021). The iron-and-aging question therefore remains open rather than settled in either direction.

Expected Benefits

High 🟩 🟩 🟩

Correction of iron deficiency and iron-deficiency anemia ⚠️ Conflicted

Ferrous bisglycinate restores ferritin and hemoglobin (the oxygen carrier of red blood cells) when stores are low. In blood donors with low ferritin, daily or alternate-day ferrous bisglycinate for 56 days lowered iron deficiency versus placebo (Karregat 2025). Against other iron forms, pooled pregnancy trials showed higher hemoglobin (Fischer 2023), and 25 mg matched 50 mg ferrous sulfate in Milman’s trial (Milman 2014). Yet 18 mg was inferior to 60 mg ferrous sulfate in iron-replete Cambodian women (Fischer 2023). Net reading: it corrects deficiency; its dose advantage is uncertain.

Magnitude: Iron deficiency at 56 days in 1% of donors on 60 mg daily versus 51% on daily placebo, odds ratio (OR, the ratio of the odds of an outcome between groups) 0.60 (95% CI, the confidence interval likely to contain the true value, 0.55–0.66) (Karregat 2025), and in 10% on 30 mg daily, OR 0.62 (95% CI 0.56–0.68) (Karregat 2025); hemoglobin higher than with other iron supplements in pregnant women by a standardized mean difference (SMD, a between-group difference in standard-deviation units, a measure of typical spread) of 0.54 (95% CI 0.15–0.94) (Fischer 2023), a pooled estimate that includes one trial since retracted (Abbas 2019).

Medium 🟩 🟩

No benefit reaches Medium: the findings on fatigue, mood, exercise and restless legs syndrome (an urge to move the legs at rest) come from trials of other iron forms, mostly ferrous sulfate, which makes them indirect for ferrous bisglycinate.

Low 🟩

Reduced fatigue in iron-deficient adults without anemia

Low iron stores without anemia can cause tiredness. A systematic review of 18 randomized trials found iron reduced self-reported fatigue but not objective physical capacity (Houston 2018). Evidence is indirect: all but one oral trial used ferrous sulfate, not ferrous bisglycinate.

Magnitude: Self-reported fatigue SMD −0.38 (95% CI −0.52 to −0.23) versus control, 4 trials, 714 participants (Houston 2018).

Better mood and memory in iron-deficient people without anemia

In non-anemic menstruating adults and youth, randomized trials pooled by Fiani showed iron improved anxiety and short-term memory, but not attention or depression (Fiani 2025). Effects were absent once iron-deficient participants were excluded (Fiani 2025). Evidence is indirect: mixed iron forms.

Magnitude: Effect size (Cohen’s d, a standardized difference where 0.5 is moderate) 0.34 for anxiety (Fiani 2025) and 0.53 for short-term memory (Fiani 2025) in the randomized trials.

Exercise capacity in iron-deficient women ⚠️ Conflicted

A Cochrane review found daily iron improved maximal and submaximal exercise performance in menstruating women (Low 2016). In iron-deficient non-anemic adults, iron did not change maximal oxygen consumption (Houston 2018). Both reviews tested other iron forms. Net reading: any gain is uncertain without anemia.

Magnitude: Maximal oxygen consumption SMD 0.11 (95% CI −0.15 to 0.37), 9 trials, 235 participants, in iron-deficient non-anemic adults (Houston 2018).

Relief of restless legs syndrome with low iron stores

In restless legs syndrome, oral iron outperformed placebo at low-normal ferritin (Wang 2009). A sleep-medicine guideline (members earn nothing from oral iron; lead author has intravenous-iron ties) suggests ferrous sulfate at ferritin ≤75 ng/mL (Winkelman 2025). Neither tested this form.

Magnitude: International Restless Legs Scale score decreased more with oral iron (10.3 points) than with placebo (1.14 points) over 12 weeks (p=0.01, the probability of a difference this large arising by chance) (Wang 2009).

Speculative 🟨

No benefit is graded Speculative: the laboratory and animal work on this chelate concerns absorption and toxicity, which the human absorption and clinical studies above already cover.

Benefit-Modifying Factors

  • Baseline iron stores: Absorption from ferrous bisglycinate falls as serum ferritin rises (Bovell-Benjamin 2000), so people with low ferritin gain most, while iron-replete users gain little, as in the Cambodian trial (Fischer 2023).

  • Genetic polymorphisms: HFE variants (in a gene that sets hepcidin levels) such as C282Y raise iron absorption, lowering need. Rare loss-of-function mutations in TMPRSS6 (a gene that switches hepcidin down) cause iron deficiency resistant to oral iron; a common variant raises iron status (Gill 2019).

  • Sex: Regular blood donors of either sex are at increased risk of iron deficiency and respond to supplementation (Karregat 2025); menstruating women are the other main group that benefits. Men and postmenopausal women are rarely deficient without blood loss.

  • Pre-existing conditions: In Crohn’s disease (an inflammatory bowel disease), iron from ferrous bisglycinate was absorbed less well than from ferrous calcium citrate (Chermesh 2006). Celiac disease (gluten-triggered gut damage), bariatric surgery and chronic inflammation also blunt oral iron response.

  • Age: In older adults, new iron deficiency usually reflects gastrointestinal blood loss, so the cause matters more than the iron form. Reduced stomach acid with age or acid-suppressing drugs lowers nonheme-iron absorption.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal adverse events ⚠️ Conflicted

Unabsorbed iron irritates the gut, causing nausea, abdominal discomfort, constipation and dark stools. Ferrous bisglycinate causes these less often than iron salts: Fischer’s meta-analysis of seven pregnancy trials found fewer events than other iron forms (Fischer 2023), as did trials by Milman (Milman 2014) and Bumrungpert, funded by supplement maker Max Biocare (Bumrungpert 2022). Two Danish pregnancy trials, partly funded by supplement makers, found low-dose iron caused no clinically significant gastrointestinal complaints (Milman 2024). Net reading: events occur but are mostly mild and less frequent than with salts.

Magnitude: Gastrointestinal adverse events incidence rate ratio (IRR, the ratio of event rates between groups) 0.36 (95% CI 0.17–0.76) versus other iron supplements in pregnant women (Fischer 2023), a pooled estimate that includes one trial since retracted (Abbas 2019); gastrointestinal side effects in 6.7% of women on 60 mg ferrous bisglycinate once daily versus 11.1% on ferrous ascorbate over 8 weeks in a GSK-sponsored trial (NCT01160198).

Medium 🟥 🟥

No risk reaches Medium: beyond gastrointestinal effects, the human data are genetic association studies, poisoning surveillance and guideline consensus, none from controlled trials of ferrous bisglycinate.

Low 🟥

Iron overload in hemochromatosis or with long-term use

Hereditary hemochromatosis (inherited iron overabsorption) loads iron into organs; the European Association for the Study of the Liver (EASL), whose members sell no supplements, advises avoiding iron supplements in it (EASL 2022). Long-term over-the-counter ferrous bisglycinate caused iron overload in a mother and daughter, improving after blood removal (Sugimori 2025).

Magnitude: Not quantified in available studies. Only case reports and guideline advice exist; no study has measured how often ferrous bisglycinate causes iron overload.

Reduced life expectancy with high iron status

Mendelian randomization (using inherited gene variants as natural experiments) found that genetically higher serum iron predicted a shorter parental lifespan and lower odds of reaching old age (Daghlas 2021). Evidence is indirect: lifelong genetic iron levels, not supplementation, were studied.

Magnitude: Per 1-standard-deviation rise in genetically predicted serum iron, 0.70 fewer years of parental lifespan (95% CI −1.17 to −0.24) (Daghlas 2021), and an OR of 0.81 (95% CI 0.70–0.93) for survival to the 90th versus 60th percentile age (Daghlas 2021).

Skin and soft-tissue infections with high iron status

A phenome-wide (hundreds of diseases) Mendelian randomization study linked genetically higher iron to more cellulitis (a bacterial skin infection) and leg abscesses (Gill 2019), though also to less hypercholesterolemia (Gill 2019). Evidence is indirect: inherited iron levels, not supplements, were studied.

Magnitude: OR 1.25 (95% CI 1.10–1.42) for cellulitis and abscess of the leg per 1-standard-deviation rise in genetically determined serum iron (Gill 2019).

Venous thromboembolism with high iron status

Mendelian randomization linked genetically higher iron status to more venous thromboembolism (blood clots in deep veins or lungs) (Gill 2019), though also to less carotid plaque (fatty deposits in neck arteries) (Gill 2019). Evidence is indirect: inherited iron levels, not supplements, were studied.

Magnitude: OR 1.37 (95% CI 1.14–1.66) for venous thromboembolism per 1-standard-deviation rise in genetically determined serum iron (Gill 2019).

Accidental iron poisoning in young children

Iron poisoning is a major cause of unintentional poisoning death in young children (Tenenbein 2005); deaths fell after US unit-dose packaging rules (Tenenbein 2005). FDA requires an overdose warning on iron-containing supplements (21 CFR 101.17). Data cover all iron products, not ferrous bisglycinate specifically.

Magnitude: Iron-poisoning deaths in US children under 6 fell from 29 in the 10 years before the 1997 packaging rule to 1 in the 5 years after (no control group) (Tenenbein 2005).

Speculative 🟨

Gut microbiome shift toward Enterobacteriaceae ⚠️ Conflicted

In iron-replete Cambodian women, ferrous bisglycinate raised gut Enterobacteriaceae, a bacterial family containing enteric pathogens (Finlayson-Trick 2023), without changing gut inflammation (Fischer 2023). Net reading: an unvalidated signal without shown harm.

Risk-Modifying Factors

  • Genetic polymorphisms: HFE C282Y homozygotes develop progressive iron loading, and the liver society EASL, whose members sell no supplements, advises them to avoid iron supplementation (EASL 2022); other HFE genotypes carry smaller, variable loading.

  • Baseline biomarkers: High transferrin saturation (the share of the blood iron carrier loaded with iron) and high ferritin signal overload; EASL, whose physicians sell no iron, uses above 45% and 200 μg/L (premenopausal women) or 50% and 300 μg/L (men, postmenopausal women) (EASL 2022).

  • Sex: Men and postmenopausal women lose little iron, so stores accumulate with age, the basis of the iron hypothesis of heart disease (Sullivan 1981). Menstruating women carry the lowest overload risk.

  • Pre-existing conditions: Hemochromatosis, transfusion-dependent anemias, chronic liver disease and heavy alcohol use raise overload risk. Inflammatory bowel disease can worsen with unabsorbed oral iron, and anemia from other causes (thalassemia trait, an inherited hemoglobin disorder, or vitamin B12 deficiency) is not corrected by iron.

  • Age: Older adults face more constipation, more interacting medications, and higher odds that iron deficiency signals gastrointestinal bleeding that supplementation could mask. Households with young children face the poisoning risk of any iron product.

Key Interactions & Contraindications

Documented interactions:

  • Levothyroxine: Ferrous sulfate taken with levothyroxine raised thyrotropin (thyroid-stimulating hormone) in hypothyroid patients (Campbell 1992). Consequence: under-treated hypothyroidism. Mitigation: doses separated by at least 4 hours.

  • Fluoroquinolone antibiotics (ciprofloxacin, norfloxacin, ofloxacin): Ferrous sulfate cut ciprofloxacin exposure by 57% (Lehto 1994) and norfloxacin exposure by 73% (Lehto 1994). Consequence: antibiotic failure. Mitigation: antibiotic taken at least 2 hours before or 6 hours after iron.

  • Tetracycline antibiotics (doxycycline, tetracycline, oxytetracycline): Ferrous sulfate seriously impaired absorption of tetracycline and its derivatives (Neuvonen 1970). Consequence: antibiotic failure. Mitigation: iron paused during the course or separated by several hours.

  • Levodopa (carbidopa-levodopa): Ferrous sulfate lowered levodopa exposure by about half through chelation (Campbell 1989). Consequence: weaker Parkinson’s symptom control. Mitigation: doses separated by at least 2 hours.

  • Bisphosphonates (bone-loss drugs: risedronate, alendronate): Ferrous iron is a divalent cation; the Actonel label states that oral medications containing divalent cations interfere with risedronate absorption (Actonel label). Consequence: reduced bisphosphonate absorption and bone protection. Mitigation: bisphosphonate taken while fasting, at least 30 minutes before iron.

  • Integrase inhibitors (drugs for human immunodeficiency virus, HIV: dolutegravir): Taken fasting, ferrous fumarate cut dolutegravir exposure by 54% in a GSK-run study (Song 2015). Consequence: weaker HIV suppression. Mitigation: dolutegravir taken 2 hours before or 6 hours after iron, or both with a meal.

  • Proton pump inhibitors (stomach-acid blockers: omeprazole, pantoprazole, esomeprazole): In hemochromatosis, proton pump inhibitors suppressed absorption of nonheme iron from a test meal (Hutchinson 2007). Consequence: slower iron repletion. Mitigation: ferritin monitoring, with intravenous iron if response stalls.

  • Calcium supplements, calcium carbonate antacids and dairy: Milk lowered iron absorption from ferrous bisglycinate from 46.3% to 11.1% (Olivares 1997), and 300–600 mg calcium cut nonheme-iron absorption by 50–60% (Hallberg 1991). Consequence: weaker repletion. Mitigation: a 2-hour gap between iron and calcium or dairy.

  • Vitamin C (additive effect): Ascorbic acid raised iron absorption from ferrous bisglycinate given in milk from 11.1% to 15.4% (Olivares 1997). Consequence: modestly better uptake, and faster loading in hemochromatosis. Mitigation: vitamin C pairing reserved for confirmed deficiency.

  • Tea and espresso coffee: Espresso and tea reduced iron absorption from ferrous bisglycinate by 50% (Layrisse 2000), while American-type coffee did not (Layrisse 2000). Consequence: weaker repletion. Mitigation: no tea or espresso for 1–2 hours around the dose.

  • Phytate-rich foods (whole grains, legumes): In whole-maize porridge, iron from ferrous bisglycinate was absorbed four times better than from ferrous sulfate (Bovell-Benjamin 2000). Consequence: phytate blunts this form less than salts. Mitigation: none needed beyond usual spacing from meals.

  • Curcumin supplements (no interaction found): In a randomized trial in 155 healthy adults, funded by curcumin supplier Gencor Pacific, 500 mg bioavailable curcumin taken with ferrous sulfate did not impair acute iron absorption (Lorinczova 2021). Consequence: no interaction found. Mitigation: none needed.

  • Regular blood donation (other intervention): In donors with low ferritin, ferrous bisglycinate lowered iron deficiency versus placebo (Karregat 2025). Consequence: complementary effect, offsetting iron removed by each donation. Mitigation: ferritin-guided dosing between donations.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Other iron-containing supplements (multivitamins with iron, heme iron from meat extracts, lactoferrin, an iron-binding milk protein): Additive iron load inferred from summed elemental iron. Consequence: more gastrointestinal effects and, over time, iron accumulation. Mitigation: total elemental iron counted across all products.

  • Iron-chelating polyphenol supplements (quercetin): Inferred from quercetin’s iron-binding chemistry, which could reduce iron uptake when taken together. Consequence: slower repletion. Mitigation: a 2-hour gap between doses.

Populations who should avoid Ferrous Bisglycinate:

  • People with hereditary hemochromatosis, whom EASL (members sell no supplements) advises to avoid iron supplementation, or with iron overload by its criteria: transferrin saturation above 45% with ferritin above 200 μg/L (premenopausal women), or 50% and 300 μg/L (men, postmenopausal women) (EASL 2022)
  • People with transfusion-dependent anemias such as thalassemia major (inferred from the iron load transfusions already impose; no human data on this form)
  • People with anemia not caused by iron deficiency, such as thalassemia trait or vitamin B12 deficiency, without documented low ferritin (inferred: iron cannot correct these and adds to stores; no human data)

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Test before starting: Measuring ferritin, transferrin saturation and hemoglobin prevents supplementing into overload, defined by EASL (non-selling physicians) as saturation above 45% with ferritin above 200 μg/L (premenopausal women), or 50% and 300 μg/L (men, postmenopausal women) (EASL 2022).

  • Lowest effective dose: Starting at 25–30 mg elemental iron limits gastrointestinal adverse events; 30 mg daily or on alternate days lowered iron deficiency in donors (Karregat 2025).

  • Alternate-day dosing: Taking iron every other day lowers hepcidin between doses and reduces gastrointestinal exposure; alternate-day dosing raised fractional absorption (the share of a dose absorbed) in iron-depleted women (Stoffel 2017).

  • Take with a small meal if needed: If nausea or abdominal pain persists, taking the dose with food reduces these gastrointestinal adverse events at the cost of somewhat lower absorption.

  • Stop at repletion: Rechecking ferritin every 8–12 weeks and stopping once stores are restored prevents iron accumulation and the long-term harms linked to high iron status.

  • Find the cause: In men and postmenopausal women, investigating gastrointestinal blood loss before supplementing prevents iron from masking bleeding from ulcers, polyps or cancer.

  • Child-proof storage: Keeping iron in child-resistant containers out of reach prevents accidental poisoning, which FDA labeling warns can be fatal in children under 6 (21 CFR 101.17).

  • Separate interacting drugs: Spacing iron 2–6 hours from levothyroxine, fluoroquinolones, tetracyclines, levodopa and dolutegravir prevents reduced drug efficacy; dolutegravir goes 2 hours before or 6 hours after iron (Song 2015).

Therapeutic Protocol

Doses below are cited to their sources; timing, cycling and titration parameters without a citation reflect common practice.

  • Prevention dose: 25 mg elemental iron daily prevented iron deficiency anemia in more than 95% of Danish pregnant women (Milman 2014); 24 mg daily was used in a Thai pregnancy trial (Bumrungpert 2022).

  • Repletion dose: 30 or 60 mg daily or on alternate days for 56 days in blood donors with low ferritin (Karregat 2025); 60 mg once daily for 8 weeks in anemic women (NCT01160198).

  • Alternate-day approach: Popularized by the ETH Zurich group of Zimmermann and Moretti, whose isotope trials found higher absorption with alternate-day dosing of ferrous sulfate (Stoffel 2017); with ferrous bisglycinate, alternate-day and daily 30 mg performed similarly (Karregat 2025).

  • Competing approach, intravenous iron: Used for malabsorption, intolerance or urgency; adding 60 mg oral iron bisglycinate to intravenous iron sucrose raised postpartum hemoglobin by only 0.4 g/dL more (Yefet 2021).

  • Time of day: Morning on an empty stomach with water or vitamin C is common, as morning doses were used in absorption trials (Stoffel 2017); doses are kept 1–2 hours from coffee, tea, dairy and calcium.

  • Half-life: Iron has no conventional half-life. Serum iron rose within 1–2 hours of ferrous bisglycinate (Bumrungpert 2022), and the hepcidin rise after 60 mg or more lasts about 24 hours (Moretti 2015).

  • Single versus split dose: Splitting one daily dose in two did not raise absorption over a single morning dose (Stoffel 2017). Doubling to 60 mg twice daily raised the 8-week hemoglobin gain only from 2.6 (NCT01160198) to 2.8 g/dL (NCT01160198).

  • Genetic polymorphisms: HFE C282Y homozygotes are excluded; in HFE carriers, lower doses and closer ferritin checks are common practice. Iron deficiency unresponsive to oral iron suggests TMPRSS6 mutations, where intravenous iron is used.

  • Sex: Menstruating women and frequent blood donors of either sex are the main users; men and postmenopausal women use it only for documented deficiency, after the cause is found.

  • Age: Older adults often start at the lower doses above or on alternate days to limit constipation; in this group, new iron deficiency usually prompts a search for gastrointestinal bleeding before treatment.

  • Baseline biomarkers: Absorption is inversely related to ferritin (Bovell-Benjamin 2000), so dose and duration are set by ferritin and transferrin saturation; iron-replete people gain little.

  • Pre-existing conditions: Inflammatory bowel disease, celiac disease, bariatric surgery, chronic kidney disease and heart failure blunt oral response, and intravenous iron is often preferred in these conditions.

Discontinuation & Cycling

  • Short-term by design: Ferrous bisglycinate is used until ferritin is restored, commonly for about 3 months after hemoglobin normalizes; long-term use is reserved for ongoing losses such as heavy menstruation or regular blood donation.

  • Withdrawal effects: None are known; stopping iron causes no rebound, but stores fall again if losses continue.

  • Tapering: Not needed; the dose can be stopped at once.

  • Persistence after stopping: In schoolchildren with low stores, ferritin gains after 12 weeks of 30 mg ferrous bisglycinate persisted 6 months after stopping (Duque 2014).

  • Cycling: Cycling is not needed to maintain efficacy; alternate-day dosing or intermittent courses guided by ferritin rechecks replace continuous daily use.

Sourcing and Quality

  • Elemental iron on the label: Doses refer to elemental iron, not chelate weight; the chelate is roughly one-fifth iron by weight, so a label stating elemental iron per serving is the useful one.

  • Branded chelate: Ferrochel, made by Albion Minerals (now part of Balchem), is the most studied form; many brands, such as Thorne, Solgar (Gentle Iron), Pure Encapsulations and Life Extension, sell ferrous bisglycinate products.

  • Third-party testing: Products certified by United States Pharmacopeia (USP), NSF International or tested by ConsumerLab verify labeled iron content and screen for contaminants such as lead.

  • Fully reacted chelate: Some products blend iron salts with glycine; looking for “ferrous bisglycinate chelate” rather than “iron (as ferrous sulfate, glycine)” ensures the studied form.

  • Combination products: Formulas pairing iron with vitamin C suit deficiency; products combining iron with calcium undercut absorption, as calcium inhibits it.

  • Packaging: Child-resistant packaging, required for iron supplements holding 250 mg or more of elemental iron per package (16 CFR 1700.14), and the FDA overdose warning statement (21 CFR 101.17) indicate compliant products.

Practical Considerations

  • Time to effect: On 60 mg daily, hemoglobin rose 0.6 g/dL by week 2 (NCT01160198), 1.2 g/dL by week 4 (NCT01160198) and 2.6 g/dL by week 8 (NCT01160198); ferritin and fatigue usually take 2–3 months.

  • Supplementing without testing: Taking iron for vague fatigue without measuring ferritin risks overload in iron-replete people, the group in whom the longevity concerns apply.

  • Misreading ferritin: Ferritin rises with inflammation independent of iron stores, so a normal ferritin with high C-reactive protein (an inflammation marker) can hide deficiency.

  • More is not proportionally better: A sixfold increase in iron dose resulted in only a threefold increase in iron absorbed (Moretti 2015).

  • Regulatory status: In the US it is sold as a dietary supplement, a category FDA labeling rules address for iron products (21 CFR 101.17); FDA raised no questions about its generally recognized as safe status for food fortification (FDA GRN 19).

  • Cost and structural bias: It is inexpensive, though dearer than ferrous sulfate. Public supplementation programs and payers buying at scale have an incentive to favor cheaper salts, which may shape guideline defaults; a narrative review names cost as limiting fortification use (Hertrampf 2004).

Interaction with Foundational Habits

  • Sleep: Indirect, potentiating where iron is low: correcting deficiency can relieve restless legs symptoms that fragment sleep (Wang 2009). No direct sedative or stimulating effect is known; timing relative to bedtime matters only for spacing from evening dairy or tea.

  • Nutrition: Direct, with blunting and potentiating foods. Milk lowers and vitamin C raises absorption from ferrous bisglycinate (Olivares 1997), and espresso and tea halve it (Layrisse 2000). Plant-based diets supply less absorbable iron; meat provides heme iron that adds to the total.

  • Exercise: Indirect: endurance training and sweat losses raise iron needs; a Cochrane review found daily iron improved exercise performance in menstruating women (Low 2016), though a systematic review found no change in maximal oxygen consumption without anemia (Houston 2018). Exercise transiently raises hepcidin, so many athletes dose in the morning before or right after training.

  • Stress management: None direct: ferrous bisglycinate has no known effect on cortisol. Indirectly, a meta-analysis found iron improved anxiety scores in non-anemic iron-deficient people (Fiani 2025), which may ease perceived stress.

Monitoring Protocol & Defining Success

Before starting, baseline testing establishes whether iron deficiency exists and excludes overload: a complete blood count with hemoglobin and red-cell size, ferritin, serum iron with transferrin saturation, and C-reactive protein to interpret ferritin. People with a family history of hemochromatosis or high transferrin saturation add HFE genotyping. In men and postmenopausal women, a confirmed deficiency prompts a search for gastrointestinal blood loss before supplementation begins.

Ongoing monitoring follows a set cadence: hemoglobin at 2–4 weeks to confirm response, then ferritin, transferrin saturation and hemoglobin at 8–12 weeks, and every 3–6 months while supplementation continues. Testing is ideally done in the morning, after at least 24 hours without iron. Success means hemoglobin in range, ferritin restored without overshooting, and improved symptoms; ferritin climbing toward overload thresholds, or no hemoglobin rise within a month, signals a dose change or a different iron route.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Ferritin Above 30 μg/L (low-ferritin cutoff used by Karregat 2025); 75 ng/mL or less is the restless legs iron-treatment threshold (American Academy of Sleep Medicine, Winkelman 2025) Expected to change: tracks repletion; also a safety check for overshoot Conventional reference range roughly 15–150 μg/L (women) and 30–400 μg/L (men), lab-dependent; rises with inflammation, so pair with C-reactive protein; the American Academy of Sleep Medicine’s members earn nothing from oral iron, while its guideline’s lead author has intravenous-iron industry ties. Sources: Karregat 2025; Winkelman 2025
Transferrin saturation 20–45%: below 20% is the restless legs iron-treatment threshold (Winkelman 2025); above 45% in premenopausal women or 50% in men and postmenopausal women flags overload (EASL 2022) Safety check: rising saturation stops or reduces use Conventional reference range roughly 20–50%; morning sample, at least 24 hours after the last iron dose; EASL members sell no iron; the restless legs guideline’s sleep-physician members earn nothing from oral iron, while its lead author has intravenous-iron industry ties. Sources: Winkelman 2025; EASL 2022
Hemoglobin 12.0–15.5 g/dL (women), 13.5–17.5 g/dL (men) (standard reference range) Expected to change: rises when anemia is corrected A rise of about 1 g/dL within 4 weeks indicates response; lab ranges vary
Mean corpuscular volume (average red-cell size) 80–100 fL (standard reference range) Expected to change: small cells normalize with repletion Distinguishes iron deficiency from B12 or folate anemia; slower to change than hemoglobin

Qualitative markers:

  • Energy levels and fatigue during the day
  • Exercise tolerance, such as breathlessness on stairs or training recovery
  • Restless legs symptoms and sleep continuity
  • Gastrointestinal tolerance: nausea, constipation, abdominal discomfort
  • Cold intolerance, headaches and concentration

Emerging Research

  • EASE-Iron pregnancy trial (NCT06014983): Randomized, double-blind; 172 pregnant participants in Vancouver receive 24 mg iron as ferrous bisglycinate or ferrous fumarate; primary endpoint maternal ferritin, with gut microbiome secondary; recruiting, completion estimated January 2027. Positive: would support the chelate as the preferred prenatal form. Null: would weaken claims of better bioavailability at equal doses.

  • Albion tolerability trial (NCT02128971): Manufacturer-sponsored, 108 anemic Indonesian women, 90 mg Ferrochel versus four iron forms and placebo for 30 days, primary endpoint gastrointestinal tolerability. Its estimated completion (August 2014) has passed; status unknown, no results posted, leaving the placebo comparison unpublished.

  • Iron and the biology of aging: A genomic scan of healthspan, lifespan and longevity flagged haem metabolism as a pathway worth further study (Timmers 2020). Interventional work testing whether keeping iron mid-range extends healthspan could weaken the case for supplementing iron-replete adults, or strengthen it for correcting deficiency.

  • Competing iron forms: In a 17-person crossover trial by industry-affiliated authors, glycoprotein matrix-bound iron produced higher serum iron than ferrous fumarate, while ferrous bisglycinate did not differ from fumarate (Secrest 2025). Larger trials could erode bisglycinate’s position as the preferred gentle form.

  • Physical capacity without anemia: An individual participant data meta-analysis is planned to test iron’s effect on physical capacity in iron-deficient non-anemic people (Dugan 2024). A positive result would lift the exercise benefit; a null result would confirm it is limited to anemia.

Conclusion

Ferrous bisglycinate is a gentle, well-studied form of supplemental iron in which iron is bound to the amino acid glycine. For health-focused adults, its value depends almost entirely on whether they lack iron. In people with low iron stores, such as menstruating women, frequent blood donors and endurance athletes, it reliably refills stores and corrects anemia, with good supporting trials from several independent groups. It causes nausea, abdominal discomfort, constipation and dark stools less often than classic iron salts, which helps people keep taking it. Claims that a smaller dose of this form outperforms standard salts are mixed. Benefits for tiredness, mood, exercise and restless legs come from studies of other iron forms and are less certain.

For people who already have enough iron, the balance shifts. The body cannot remove surplus iron, genetic studies tie higher lifelong iron to a shorter life and more skin infections, and people with inherited iron overload are harmed by it. These long-term concerns come from genetic and population data rather than trials of this product, so their size for any one user is unknown. Much of the early research came from the manufacturer or company-funded studies, and independent trials have tempered some early claims. Iron tablets are also a well-known poisoning danger for young children in the home. Overall, the evidence supports this form as a tolerable way to correct a confirmed deficiency, not as a general longevity supplement.

Top - Benefits - Risks - Protocol